AstraZeneca Reports IMFINZI-Based Regimen Cuts Death Risk by 22% in Early Gastric Cancer
WILMINGTON, DE — AstraZeneca announced new data from its Phase III MATTERHORN trial showing that its immunotherapy IMFINZI (durvalumab), when used in combination with standard FLOT chemotherapy, reduced the risk …
AstraZeneca Reports IMFINZI-Based Regimen Cuts Death Risk by 22% in Early Gastric Cancer Read More